From research grants, to exciting discoveries and treatment breakthroughs, read the latest research news from the Melanoma Institute Australia team as we work tirelessly towards our goal of zero deaths from melanoma.
From just 16 weeks’ survival to long term disease control
Newly released long-term data from a groundbreaking clinical trial for advanced melanoma patients whose disease had spread to their brain has proven that long-term disease control has been achieved for over 50% of patients given combination immunotherapy as first line treatment.
MIA’s ground-breaking work recognised with two Cancer NSW Awards
We are proud to announce that the ground-breaking work of the MIA team has been recognised with two prestigious 2024 NSW Premier’s Awards for Outstanding Cancer Research.
Be part of research study on genetic information and testing
Patients, and families of patients, impacted by advanced melanoma are invited to participate in an online interview to explore their views, experiences, and needs related to genetic information, support and testing.
Together, Amplifying Impact at #AMC2024
Hosted by MIA in Sydney, AMC2024 brought together 776 multidisciplinary delegates to engage in insightful discussions, presentations and workshops, all dedicated to reaching our common goal of zero deaths from melanoma. See our AMC2024 photo album.
$2.1 million to help boost cancer research in NSW
This World Cancer Research Day, the NSW Government is committing $2.1 million in research grant funding, with almost $700k awarded to MIA's Prof Long for an imaging system that will allow researchers to better visualise & understand tumour cell interactions.
MIA researchers sharing world stage at ESMO24
MIA’s leading experts and early career researchers have shared the world stage at the annual European Society for Medical Oncology (ESMO) Congress in Barcelona.
Preventing disease recurrence in BRAF positive melanoma patients
Final results of the COMBI-AD clinical trial, published in New England Journal of Medicine, show significant benefit in preventing disease progression in BRAF positive Stage III melanoma patients.
Australian researchers spearhead cancer treatment revolution
In what has been described as a cancer treatment revolution, the pre-surgery use of combination immunotherapy looks to become standard treatment for melanoma and impact other cancers across the globe.
Prof Georgina Long elected Fellow of Australian Academy of Science
Congratulations to Professor Georgina Long AO, elected as a Fellow of the Australian Academy of Science in recognition of her outstanding contribution to science.
PBS listing is life-changing news
The federal government has announced a new immunotherapy treatment for advanced melanoma patients has been added to PBS, significantly reducing the cost of the life-saving treatment.
Four MIA researchers receive Tour de Cure grants
We are delighted to have been successful in receiving four research grants recently awarded by Tour de Cure Australia.
NADINA trial “will shape medicine in 2024”
A clinical trial, developed by MIA researchers in collaboration with international colleagues, has been named by prestigious journal Nature Medicine as one of 11 clinical trials likely to have the most impact on global medicine in the year ahead.